ArticleBMC medical informatics and decision making2023
XGBoost-SHAP-based interpretable diagnostic framework for alzheimer's disease.
Article in BMC medical informatics and decision making, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparing Traditional Versus AI-Assisted TMJ Disorder Management Approaches: A Systematic Review and Meta-Analysis.Clinical and experimental dental research · 2026Pooled it
- Artificial Intelligence in Temporomandibular Joint Disorders: An Umbrella Review.Clinical and experimental dental research · 2025Pooled it
- Clinically interpretable nomogram incorporating radiomics and deep learning feature fusion from abdominal CT for preclinical type 2 diabetes.Abdominal radiology (New York) · 2026Article
- DiAbot: A Conversational AI System Coupling Large Language Models with an Interpretable Decision Tree for CDR-Style Dementia Screening.Bioengineering (Basel, Switzerland) · 2026Article
- Feature Selection Analysis and Robustness to Missing Data for Sensor-Based Prognostic Modeling of Alzheimer's Disease Progression.Sensors (Basel, Switzerland) · 2026Article
- Development and Validation of an XGBoost-SHAP Model for Predicting Adverse Outcomes in Elderly Cardiovascular Patients With Polypharmacy: A Retrospective Cohort Study.Pharmacology research & perspectives · 2026Article
- Developing a prediction model to predict the incidence of metastasis in lung cancer patients using artificial intelligence techniques.BMC pulmonary medicine · 2026Article
- CTGAN-Based Data Augmentation and XGBoost-LSTM Strength Prediction of CSG.Materials (Basel, Switzerland) · 2026Article
- Mechanisms and integrative machine learning approaches to blood-brain barrier biomarker profiling for personalized ischemic stroke management.Physiological reports · 2026Review
- The influence of anti-involution training on the critical thinking of young healthcare professionals in dental outpatient clinics: a pre-post quasi-experimental study.BMC medical education · 2026Article
- SRSF1 as a promising biomarker and key player in the pathogenesis of Alzheimer's disease.Molecular medicine reports · 2026Article
- Explainable machine learning for the prediction of Alzheimer's disease-related cognitive impairment: a consensus feature selection approach.BMC medical informatics and decision making · 2026Article
- A machine learning-based interpretable model for predicting pancreatic cancer in chronic pancreatitis patients with focal pancreatic lesions.BMC cancer · 2026Article
- Artificial intelligence for predicting transient hypocalcemia after total thyroidectomy.Scientific reports · 2026Article
- Divide-and-conquer analysis reveals hidden immune cell influencers across the placenta in preeclampsia.BioData mining · 2026Article
- Amyloid-beta statuses prediction with free water MR imaging features in Alzheimer's disease using machine learning models.BMC medical imaging · 2026Article
- UbiQTree: Uncertainty quantification in XAI with tree ensembles.Patterns (New York, N.Y.) · 2026Article
- DSPONVNet: a multimodal deep learning model integrating intraoperative monitoring and clinical features for predicting postoperative nausea and vomiting risk.BMC medical research methodology · 2026Article
- Superficial and deep white matter brain alterations discriminate tinnitus in older adults.Brain structure & function · 2026Article
- Tabular LLMs for Interpretable Few-Shot Alzheimer's Disease Prexdiction with Multimodal Biomedical Data.ArXiv · 2026Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDue to the class imbalance issue faced when Alzheimer's disease (AD) develops from normal cognition (NC) to mild cognitive impairment (MCI), present clinical practice is met with challenges regarding the auxiliary diagnosis of AD using machine learning (ML). This leads to low diagnosis performance. We aimed to construct an interpretable framework, extreme gradient boosting-Shapley additive explanations (XGBoost-SHAP), to handle the imbalance among different AD progression statuses at the algorithmic level. We also sought to achieve multiclassification of NC, MCI, and AD.
methodsWe obtained patient data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including clinical information, neuropsychological test results, neuroimaging-derived biomarkers, and APOE-ε4 gene statuses. First, three feature selection algorithms were applied, and they were then included in the XGBoost algorithm. Due to the imbalance among the three classes, we changed the sample weight distribution to achieve multiclassification of NC, MCI, and AD. Then, the SHAP method was linked to XGBoost to form an interpretable framework. This framework utilized attribution ideas that quantified the impacts of model predictions into numerical values and analysed them based on their directions and sizes. Subsequently, the top 10 features (optimal subset) were used to simplify the clinical decision-making process, and their performance was compared with that of a random forest (RF), Bagging, AdaBoost, and a naive Bayes (NB) classifier. Finally, the National Alzheimer's Coordinating Center (NACC) dataset was employed to assess the impact path consistency of the features within the optimal subset.
resultsCompared to the RF, Bagging, AdaBoost, NB and XGBoost (unweighted), the interpretable framework had higher classification performance with accuracy improvements of 0.74%, 0.74%, 1.46%, 13.18%, and 0.83%, respectively. The framework achieved high sensitivity (81.21%/74.85%), specificity (92.18%/89.86%), accuracy (87.57%/80.52%), area under the receiver operating characteristic curve (AUC) (0.91/0.88), positive clinical utility index (0.71/0.56), and negative clinical utility index (0.75/0.68) on the ADNI and NACC datasets, respectively. In the ADNI dataset, the top 10 features were found to have varying associations with the risk of AD onset based on their SHAP values. Specifically, the higher SHAP values of CDRSB, ADAS13, ADAS11, ventricle volume, ADASQ4, and FAQ were associated with higher risks of AD onset. Conversely, the higher SHAP values of LDELTOTAL, mPACCdigit, RAVLT_immediate, and MMSE were associated with lower risks of AD onset. Similar results were found for the NACC dataset.
conclusionsThe proposed interpretable framework contributes to achieving excellent performance in imbalanced AD multiclassification tasks and provides scientific guidance (optimal subset) for clinical decision-making, thereby facilitating disease management and offering new research ideas for optimizing AD prevention and treatment programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.